07 Jan 2001

Eremfat® 150 (Eremfat® 150/-300/-450/-600 Filmtabletten) - Deutschland

Updated: 07 Jan 2001

Eremfat® 150 | -300 | -450 | -600; -Sirup; -i.v. 300 mg | -600 mg

Tuberkulose (in Komb. mit anderen Tuberkulosemitteln). Zur Kombinationsbehandl. bei Lepra u. Buruli ulcus (Erreger: Mycobacterium leprae, bzw. M. ulcerans). Meningokokken- Meningitis-Prophylaxe.

Eremfat® 150 Description, Presentation and Dosage

Eremfat® 150 Description

Eremfat® 150 Drug Class Description

Einzelstoffe

Eremfat® 150 Drug Description

1 Filmtbl. enth.: Rifampicin 150 mg/300 mg/450 mg/600 mg.

Eremfat® 150 Generic Name

Eremfat® 150/-300/-450/-600 Filmtabletten

Eremfat® 150 Presentation

Eremfat® 150 Presentation

Eremfat® 150/-300/-450/-600; -Sirup; -i.v. 300 mg/-600 mg

Eremfat® 150 Manufacturer

Fatol

Related Learning Zones

CSU Knowledge Centre and CME

CSU Knowledge Centre and CME

This Knowledge Centre is intended for allergists, immunologists, dermatologists and other healthcare professionals involved in the treatment and management of Chronic Spontaneous Urticaria (CSU). In the Knowledge Centre, you will find a disease overview, symposium highlights platform, video channel and additional resources including an events calendar and useful external links. This resource has been given a whole new look and feel, intended to improve accessibility and visual appeal. Recent content additions include a frequently asked questions section, case studies from urticaria experts Professor Christian Vestergaard and Professor Torsten Zuberbier and information on the TARGET My Hives app.

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis Knowledge Centre

IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.

This resource has been developed in collaboration with Novartis Pharma AG.

Eremfat® 150 Dosage

Eremfat® 150 Adult Dosage

Poly(O-2-hydroxypropyl-O-methyl)cellulose, Croscarmellose-Natrium, Magnesiumstearat, Talkum, Farbstoffe: E 171, E 172, Crospovidon, Sorbitol.

Eremfat® 150 Child Dosage


Eremfat® Sirup Trockensirup
Zus.: 5 ml enth.: Rifampicin 100 mg.
Weit. Bestandteile: Saccharose 2,16 g, Natriumbenzoat (als Konservierungsmittel), Aromastoffe.

Eremfat® i.v. 300 mg/-600 mg Trockensubstanz u. Lösungsmittel
Zus.: 1 Inj.-Fl. enth.: Rifampicin-Natrium 308,2 mg mg/616,4 mg (entspr. 300 mg/600 mg Rifampicin).
Weit. Bestandteile: Natriumascorbat 5 mg/10 mg.

Eremfat® 150 Elderly Dosage

5 ml entspr. 0,18 BE.

Eremfat® 150 Precautions, Reactions and Contraindications

Eremfat® 150 Special Precautions

Eremfat® 150 Special Precautions

R 15

Eremfat® 150 Adverse Reactions

Eremfat® 150 Adverse Reactions

R 15

Related Drugs - Tropical Medicine

Back to top